Maks_Lab
Shares of Guardant Health (NASDAQ:GH) fell 11% Monday morning within the wake of news that the corporate had entered right into a $400M at-the-market stock sale settlement.
Late Friday, Guardant mentioned in a submitting that it had entered into an open market sale settlement with Jefferies for an ATM program that might generate gross proceeds of as much as $400M.
Guardant lately launched a blood-based check referred to as Shield for the detection of colorectal most cancers. The product will probably compete towards stool-based exams marketed by Exact Sciences (EXAS) and Geneoscopy.
Source: Seekingalpha